Diablo Clinical Research, Inc.

Summary

Diablo Clinical Research, Inc. is a medical facility located in Walnut Creek, California. This center is recognized for care of Diabetes, Type 2 Diabetes, Obesity, Type 1 Diabetes, Childhood Obesity and other specialties. Diablo Clinical Research, Inc. is involved with conducting 192 clinical trials across 133 conditions. There are 3 research doctors associated with this hospital, such as Mark Christiansen, MD, Helen L Stacey, and Bonnie S. Kimmel.

Top PIs

Clinical Trials running at Diablo Clinical Research, Inc.

Obesity

Diabetes

Type 1 Diabetes

Childhood Obesity

Cardiovascular Disease

Hypothyroidism

Type 2 Diabetes

C. diff infection

Diabetic Neuropathy

Coronary Heart Disease

Eloralintide

for Obesity

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

Recruiting

2 awards

Phase 3

Maridebart Cafraglutide

for Cardiovascular Disease

The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

Recruiting

1 award

Phase 3

2 criteria

Cagrilintide

for Obesity

This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participants will either get cagrilintide or placebo. Which treatment participants get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. Possible side effects will be followed carefully during the study. For each participant, the study will last for about 1 year and 6 months.

Recruiting

1 award

Phase 3

2 criteria